Tertomotide

Summary

Tertomotide (CHEMBL2108308) is a phase-3 clinical-stage protein; indicated across 7 conditions including exocrine pancreatic carcinoma and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 7 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108308
Name	Tertomotide
Type	Protein
Max phase	3

Also known as: GV-1001, Gv1001, GV1001, Tertomotida, Tertomotide, TERTOMOTIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
benign prostatic hyperplasia	2	MONDO:0010811	EFO:0000284
progressive supranuclear palsy	2	MONDO:0019037	MONDO:0019037
melanoma	1	MONDO:0005105	EFO:0000756

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	7
PHASE3	5
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05303701	PHASE3	NOT_YET_RECRUITING	GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer’s Disease(AD)
NCT00358566	PHASE3	TERMINATED	GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
NCT01579188	PHASE3	UNKNOWN	Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer
NCT02854072	PHASE3	UNKNOWN	A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
NCT04032067	PHASE3	COMPLETED	Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
NCT00444782	PHASE2	COMPLETED	A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.
NCT01247623	PHASE1/PHASE2	COMPLETED	Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma
NCT02855892	PHASE2	COMPLETED	A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
NCT03184467	PHASE2	COMPLETED	Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
NCT03959553	PHASE2	WITHDRAWN	GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer’s Disease (AD)
NCT05189210	PHASE2	COMPLETED	GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer’s Disease (AD)
NCT05819658	PHASE2	COMPLETED	GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
NCT06235775	PHASE2	COMPLETED	Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
NCT06625710	PHASE1	COMPLETED	Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).